Results released
Open the filing on sec.gov
Intellia Therapeutics, Inc. (NTLA)
Nasdaq: NTLA · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA · filing with the SEC since 2015
The companyfiscal 2025, as filed
Revenue$67.7M+16.9%
Net income-$413M+20.5%
Earnings per share$-3.81+27.4%
Operating cash flow-$395M-13.1%
Cash$155M-17.8%
Debtn/a
Shareholders’ equity$671M-23.0%
Shares, diluted108.4M+9.6%
Return on equity-61.5%
The recordfrom its filings
Filings in 202670
Newest filingNov 12 · 8-K
Annual reportFeb 26, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$2.3M
Insider buys, 12 months$1.4M
Patents granted15
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $52.9MNet income -$426MCash from operations -$355Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Large holder notice
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.